Get to know our clinical trials
“Clinical trial investigating how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumors)”
THIS STUDY IS OPEN TO ADULTS WITH ADVANCED OR METASTATIC SOLID TUMORS, SUCH AS NON-SMALL CELL LUNG CANCER, HEAD AND NECK SQUAMOUS CELL CARCINOMA, TRIPLE-NEGATIVE BREAST CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, BLADDER CANCER, VULVAR CANCER, AND CERVICAL CANCER. PATIENTS MAY PARTICIPATE IF NO STANDARD TREATMENT OPTIONS ARE AVAILABLE TO THEM AND THEY HAVE A MEASURABLE LESION OUTSIDE THE CENTRAL NERVOUS SYSTEM. THE AIM OF THIS STUDY IS TO DETERMINE HOW WELL BI 3822971 IS TOLERATED BY PEOPLE WITH THESE TYPES OF CANCER. THE RESEARCHERS ALSO SEEK TO ESTABLISH A DOSE AND DOSING SCHEDULE FOR BI 3822971 THAT ARE SAFE AND WELL TOLERATED.
Technical Summary
- FIRST-IN-HUMAN, OPEN-LABEL PHASE I TRIAL TO DETERMINE THE SAFETY AND TOLERABILITY OF BI 3822971 IN PATIENTS WITH INOPERABLE ADVANCED OR METASTATIC SOLID TUMORS.
- Code EudraCT: 2026-525785-22-00
- Protocol number: 2015-0001
- Promoter: Boehringer Ingelheim España, S.A.
- Molecule/Drug: BI 3822971
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.